XP Chemistries AB is a Sweden-based chemical, biological and pharmaceutical manufacturer. The Company has an international patent portfolio covering sustainable nature-inspired technologies optimal combinations of catalytic processes for the production of bio-based chemicals.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
04/09/26	SEK 0.2100	+15.38%	545,310
03/09/26	SEK 0.1820	-2.15%	284,460
02/09/26	SEK 0.1860	+5.68%	454,177
01/09/26	SEK 0.1760	-0.56%	987,841
31/08/26	SEK 0.1770	0.00%	77,578

Delayed Quote Nasdaq Stockholm

More quotes

Market Closed - Nasdaq Stockholm 17:00:00 04/09/2026 BST			5-day change	1st Jan Change
0.2100 ^SEK	+15.38%		+18.64%	+16.99%

08-25	XP Chemistries AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-25	XP Chemistries Q2 Net Sales Amounted To SEK 59,000	RE

Market Cap	65.94M 6.89M 5.93M 5.58M 5.1M 9.54M 651M 9.56M 25.59M 334M 25.88M 25.32M 1.08B	P/E 2024	-1.48x	P/E 2025	-5.22x
Enterprise Value	50.71M 5.3M 4.56M 4.29M 3.92M 7.33M 500M 7.35M 19.68M 257M 19.9M 19.47M 827M	EV / Sales 2024	43.7x	EV / Sales 2025	126x
Free-Float	44.34%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq Stockholm	XPC	Delayed
Deutsche Boerse AG	86Q	Delayed
Börse Stuttgart	86Q	Delayed
Boerse Muenchen	86Q	Real-time

08-25	XP Chemistries AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-25	XP Chemistries Q2 Net Sales Amounted To SEK 59,000	RE
05-22	XP Chemistries reports Q1 operating profit of SEK -3.07 mln	RE
05-22	XP Chemistries AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Xp Chemistries receives patent in Japan	RE
02-19	XP Chemistries Q4 operating loss SEK 3.3 mln	RE
02-19	XP Chemistries AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
12-16	XP Chemistries signs loi with European distributor for launch of capsaicin for animal feed	RE
11-20	XP Chemistries Q3 operating loss SEK 2.6 mln	RE
11-20	XP Chemistries AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
26/08/25	XP Chemistries AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
26/08/25	XP Chemistries Q2 operating loss SEK 4.6 mln	RE
10/07/25	XP Chemistries decides on directed share issue	RE

XP Chemistries AB Share Price

Stocks

XPC

SE0016787279

Pharmaceuticals

Valuation : XP Chemistries AB

Chart: XP Chemistries AB

Latest news : XP Chemistries AB

Quotes and Performance

Price Extremes

Managers and Directors : XP Chemistries AB

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 day	+15.38%
1 week	+18.64%
Current month	+18.64%
1 month	+22.09%
3 months	+16.99%
6 months	+12.00%
Current year	+16.99%

1 week	0.17	0.22
1 month	0.16	0.22
Current year	0.15	0.22
1 year	0.15	0.33
3 years	0.03	0.5
5 years	0.03	4.5
10 years	0.03	4.5

Manager	Title	Age	Since
Erik Nelsson CEO	Chief Executive Officer	43	31/12/2020
Anders Frejdh DFI	Director of Finance/CFO	52	31/12/2020
Shuang Zheng Lin CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Armando Córdova CHM	Chairman	56	31/12/2014
Samson Afewerki BRD	Director/Board Member	41	31/12/2014
Anna Svantes BRD	Director/Board Member	35	31/12/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/04/24	Erik Nelsson	Buy	Chief Executive Officer	20,000	0.0136%
15/04/24	Erik Nelsson	Buy	Chief Executive Officer	30,000	0.0204%
15/04/24	Erik Nelsson	Buy	Chief Executive Officer	50,000	0.0340%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
XP CHEMISTRIES AB	+15.38%	+18.64%	-20.75%	-52.91%	6.89M
ELI LILLY AND COMPANY	-0.88%	-2.15%	+58.05%	+105.91%	1,024B
JOHNSON & JOHNSON	-1.15%	+2.68%	+54.25%	+71.29%	663B
ABBVIE INC.	-1.44%	+0.38%	+20.65%	+75.54%	453B
ROCHE HOLDING AG	+0.14%	-0.47%	+30.20%	+40.61%	352B
NOVARTIS AG	-1.33%	+4.72%	+24.62%	+47.60%	304B
ASTRAZENECA PLC	-1.15%	+0.30%	-0.69%	+11.83%	252B
AMGEN INC.	-1.55%	+1.11%	+54.15%	+72.13%	236B
NOVO NORDISK A/S	-0.88%	+1.15%	-14.60%	-54.84%	206B
GILEAD SCIENCES, INC.	-0.15%	+3.65%	+31.24%	+100.90%	187B
Average	+0.70%	+2.85%	+23.71%	+41.81%	367.84B
Weighted average by Cap.	-0.96%	+0.55%	+37.63%	+67.00%

	2024	2025
Net sales	284K 29.68K 25.54K 24.03K 21.95K 41.06K 2.8M 41.17K 110K 1.44M 111K 109K 4.63M	327K 34.22K 29.45K 27.71K 25.31K 47.35K 3.23M 47.48K 127K 1.66M 129K 126K 5.34M
Net income	-7.13M -746K -642K -604K -551K -1.03M -70.4M -1.03M -2.77M -36.12M -2.8M -2.74M -116M	-8.52M -891K -766K -721K -659K -1.23M -84.09M -1.24M -3.31M -43.14M -3.34M -3.27M -139M
Net Debt	-2.15M -224K -193K -182K -166K -310K -21.17M -311K -832K -10.86M -842K -824K -34.99M	-15.23M -1.59M -1.37M -1.29M -1.18M -2.2M -150M -2.21M -5.91M -77.1M -5.98M -5.85M -248M